SCHEMBL23748321

SCHEMBL23748321

C=CCNC(=O)c1[nH]ccc(=O)c1OCc1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.51
MAPT P10636 3/20 0.43
ALDH1A1 P00352 5/20 0.41
HPGD P15428 3/20 0.41
LMNA P02545 1/20 0.41
KDM4E B2RXH2 2/20 0.41
RAB9A P51151 2/20 0.41
NPC1 O15118 1/20 0.41
CYP1A2 P05177 3/20 0.40
CYP2C9 P11712 2/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C19 P33261 1/20 0.40
USP2 O75604 1/20 0.40
TSHR P16473 1/20 0.40
HSD17B10 Q99714 1/20 0.40
THRB P10828 1/20 0.39
RECQL P46063 1/20 0.39
L3MBTL1 Q9Y468 3/20 0.39
TP53 P04637 1/20 0.39
NSD2 O96028 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23748281 0.89 POLB (0.49) POLBMAPTALDH1A1HPGDLMNA
SCHEMBL23748352 0.87 POLB (0.47) POLBALDH1A1KDM4ERAB9ANPC1
SCHEMBL24353633 0.86 POLB (0.46) POLBMAPTALDH1A1KDM4ERAB9A
SCHEMBL24354319 0.85 POLB (0.46) POLBALDH1A1LMNAKDM4ERAB9A
SCHEMBL23748282 0.83 POLB (0.53) POLBALDH1A1HPGDLMNAUSP2
SCHEMBL10188493 0.82 POLB (0.60) POLBMAPTALDH1A1HPGDLMNA
SCHEMBL24353896 0.81 POLB (0.49) POLBMAPTALDH1A1LMNAUSP2
SCHEMBL24353890 0.81 POLB (0.51) POLBMAPTALDH1A1LMNAUSP2
SCHEMBL23748298 0.80 POLB (0.47) POLBALDH1A1HPGDLMNAKDM4E
SCHEMBL10188488 0.80 POLB (0.64) POLBALDH1A1HPGDLMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023018913-A1 POLYCYCLIC CAP-DEPENDENT ENDONUCLEASE INHIBITORS FOR TREATING OR PREVENTING INFLUENZA MERCK SHARP & DOHME LLC (US) 2023-02-16 WO disclosed
US-20230002409-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS JANSSEN BIOPHARMA INC (US) 2023-01-05 US disclosed
US-11312727-B1 Macrocyclic flu endonuclease inhibitors Janssen Biopharma, Inc. (US) 2022-04-26 US disclosed
EP-3864020-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS Janssen BioPharma, Inc. (US) 2021-08-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002409-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS ACE, PNP, FEN1 POLB 74/4885MAPT 2999/4885ALDH1A1 2073/4885
US-11312727-B1 Macrocyclic flu endonuclease inhibitors ACE, FEN1, PNP POLB 32/4885MAPT 3026/4885ALDH1A1 1487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.